Yuekang Pharmaceutical: YKYY017 nebulized inhalation agent has received clinical trial approval for new indications.

On August 5, Yuekang Pharmaceutical announced that the company recently obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, which approves the use of YKYY017 aerosol inhalation for the treatment and prevention of respiratory infections associated with human coronavirus OC43.